Pharmagreen Biotech Inc.
PHBI · OTC
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | 0.01 | 0.05 | 0.04 |
| FCF Yield | -1.01% | -22.61% | -10.57% | -2.55% |
| EV / EBITDA | -3.22 | 26.48 | 22.48 | -2.21 |
| Quality | ||||
| ROIC | 8.93% | 26.21% | 72.10% | 52.93% |
| Gross Margin | 50.91% | -215.01% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.03 | 0.13 | 0.49 | 0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 61.96% | 82.69% | -106.99% | 66.08% |
| Safety | ||||
| Net Debt / EBITDA | -0.37 | 14.09 | 1.70 | -0.07 |
| Interest Coverage | -7.46 | -3.91 | -22.65 | -0.98 |
| Efficiency | ||||
| Inventory Turnover | 0.21 | 1.08 | 0.00 | 0.00 |
| Cash Conversion Cycle | -172,567.77 | -28,163.39 | 0.00 | 0.00 |